ZyVersa Therapeutics Management
Management criteria checks 1/4
ZyVersa Therapeutics' CEO is Steve Glover, appointed in Dec 2022, has a tenure of 1.42 years. total yearly compensation is $993.22K, comprised of 55.4% salary and 44.6% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $6.92K. The average tenure of the management team and the board of directors is 1.4 years and 1.3 years respectively.
Key information
Steve Glover
Chief executive officer
US$993.2k
Total compensation
| CEO salary percentage | 55.4% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.4yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$993k | US$550k | -US$106m |
| Sep 30 2023 | n/a | n/a | -US$88m |
| Jun 30 2023 | n/a | n/a | -US$98m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$1m | US$451k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$2m | US$451k | -US$8m |
| Dec 31 2020 | US$451k | US$451k | -US$13m |
Compensation vs Market: Steve's total compensation ($USD993.22K) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Glover (63 yo)
1.4yrs
Tenure
US$993,217
Compensation
Mr. Stephen C. Glover, also known as Steve, serves as Chairman of the Board at Ambrx Biopharma Inc. since May 18, 2023. He has been a Director of Incon Co., Ltd. since December 2018.Mr. Glover is a Co-Fou...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.4yrs | US$993.22k | 0.17% $ 6.9k | |
| CFO & Secretary | 1.4yrs | US$573.36k | 0.017% $ 677.0 | |
| Chief Commercial Officer | 1.4yrs | US$486.69k | 0% $ 0 | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | 0.0097% $ 391.3 |
1.4yrs
Average Tenure
67yo
Average Age
Experienced Management: ZVSA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.4yrs | US$993.22k | 0.17% $ 6.9k | |
| Chief Medical Officer | no data | no data | 0.0097% $ 391.3 | |
| Independent Director | 1.3yrs | US$80.14k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | US$521.91k | no data | |
| Independent Director | 1.4yrs | US$80.64k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$72.90k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.3yrs
Average Tenure
64yo
Average Age
Experienced Board: ZVSA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.